Three independent forecasts pointed to the same reset this week: preventive care and chronic disease management are becoming the revenue core of companion animal health. That shift raises the stakes on advanced-therapy workflow readiness, refill retention, and recurring-care infrastructure.
This edition tracks competitive pressure on parasite-prevention refills, premium nutrition sales, and independent practice workload. Merck and CAPC kept parasite prevention in focus. Freshpet’s advertising-claims review, The Farmer’s Dog’s Walmart test, and AVMA data added pressure on claims language, sales channels, and clinic workflow.
State policy drove this week’s biggest pet Rx signals. New telehealth, VCPR, dispensing, and licensure moves in four states, plus FDA’s first generic injectable robenacoxib approval, reshaped clinic control over follow-up, hiring speed, and formulary economics.
FDA approval of NUMELVI, a new JAK inhibitor for canine allergic dermatitis, and Zoetis’ genomics acquisition highlight shifting control points in the veterinary prescription market. PETMETRIX PULSE examines protocol control, clinic launch sequencing, and emerging upstream competition.
The pet Rx market battlefield is moving upstream. Chewy is entering clinics and vet workflow to capture default refills, while the Covetrus–MWI merger concentrates distribution leverage and risk. With FTC scrutiny hardening and premium therapeutics accelerating, operators should prioritize refill-without-friction, consolidation readiness, and payment/claims automation.
